Travere Therapeutics
TVTX
111 hedge funds and large institutions have $694M invested in Travere Therapeutics in 2016 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 53 increasing their positions, 31 reducing their positions, and 18 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 31
36% more capital invested
Capital invested by funds: $509M → $694M (+$185M)
7% less funds holding
Funds holding: 119 → 111 (-8)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
23% less call options, than puts
Call options by funds: $28.5M | Put options by funds: $36.7M
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.4M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$8.9M |
| 3 |
Millennium Management
New York
|
+$7.02M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$6.8M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$6.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Senzar Asset Management
New York
|
-$12.7M |
| 2 |
BC
Broadfin Capital
New York
|
-$4.81M |
| 3 |
AC
Amici Capital
New York
|
-$4.53M |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$3.19M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$2.65M |
TVTX Hedge Fund Activity: Q2 2016 in Review
111 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2016, worth a combined $694M — up 36% from $509M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of TVTX and 11 opened new positions — a net loss of 7 holders — while 31 trimmed existing stakes and 53 added.
The largest buyer was Fidelity Investments, adding an estimated $12.4M. The largest seller was Senzar Asset Management, cutting an estimated $12.7M.
- 111 institutional investors held Travere Therapeutics (TVTX) as of Q2 2016, down from 119 in Q1 2016.
- Funds reported $694M of Travere Therapeutics stock for Q2 2016, up 36% quarter-over-quarter.
- 11 funds opened new Travere Therapeutics positions in Q2 2016 and 18 closed out, a net change of -7 holders.
- The largest Travere Therapeutics buyer in Q2 2016 was Fidelity Investments, an estimated $12.4M added.
- The largest Travere Therapeutics seller in Q2 2016 was Senzar Asset Management, an estimated $12.7M sold.
Based on aggregated 13F filings for Q2 2016.